Wayoff-OZ Tablet contains a combination of Ofloxacin 200 mg and Ornidazole 500 mg, formulated to provide broad-spectrum antimicrobial activity against a variety of bacterial and protozoal infections. Ofloxacin, a fluoroquinolone antibiotic, exerts its effect by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial DNA replication, transcription, repair, and recombination. Ornidazole, a nitroimidazole derivative, targets anaerobic bacteria and protozoa by causing DNA strand breakage and inhibiting nucleic acid synthesis. This synergistic combination is particularly effective in treating mixed infections involving both aerobic and anaerobic organisms, including gastrointestinal infections, genitourinary tract infections, and certain respiratory tract infections. Wayoff-OZ is indicated for the management of infections such as bacterial dysentery, amoebiasis, trichomoniasis, and pelvic inflammatory disease. The tablet should be administered as prescribed by a healthcare professional, with dosage adjustments based on the severity of infection and patient response. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, and it is contraindicated in pregnancy and lactation. Adverse effects may include gastrointestinal disturbances, dizziness, and hypersensitivity reactions. Proper adherence to the prescribed regimen is essential to prevent resistance development and ensure therapeutic efficacy.